[PDF] Top 20 EFECTO DEL MEDIO DE CULTIVO IN VITRO Y LA FUENTE NITROGENADA SOBRE EL CRECIMIENTO DEL COCUY (Agave cocui Trelease)
Has 10000 "EFECTO DEL MEDIO DE CULTIVO IN VITRO Y LA FUENTE NITROGENADA SOBRE EL CRECIMIENTO DEL COCUY (Agave cocui Trelease)" found on our website. Below are the top 20 most common "EFECTO DEL MEDIO DE CULTIVO IN VITRO Y LA FUENTE NITROGENADA SOBRE EL CRECIMIENTO DEL COCUY (Agave cocui Trelease)".
AKT Inhibition in Solid Tumors With AKT1 Mutations.
... of AKT1 (number of mutant and wildtype copies) or co-incident tumor mutations influenced AZD5363 response, we performed whole exome or targeted sequencing of archival and fresh pre-treatment tumors ... See full document
6
Phosphorylation-Dependent Inhibition of Akt1
... for Akt1. It is well established that hyper-phosphorylation of Akt1 at both regulatory sites is linked to poor prognoses and therapeutic resistance ...locks Akt1 into the auto-inhibited or PH-in ... See full document
13
Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
... Genomic DNA was subjected to whole-exome sequen- cing using the Ion AmpliSeq Cancer Hotspot Panel v.2 (Life Technologies) according to the manufacturer’ s in- structions. The purified library was sequenced on an Ion PGM ... See full document
28
Phase II trial of AKT inhibitor MK 2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
... PTEN mutations or PTEN ...target inhibition at tolerable doses in heavily pre-treated patients with pathway activation, as well as tumor heterogeneity and evolution in markers such as PTEN conferring chal- ... See full document
10
Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors
... Western blot analysis was carried out according to standard procedures using enhanced-chemilum- inescence detection (GE Life Science, Chicago, IL, USA). Tumor tissue lysates were prepared using an electric homogenizer ... See full document
26
Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo
... human tumors, including hematopoietic malignancies (leukemia, lymphoma, and multiple myeloma) as well as solid tumors (such as head and neck, breast, and prostate cancers) ...JAK2 mutations ... See full document
52
The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells
... Mutant Akt1, mutant PIK3CA or PTEN loss enhances formation of lung cancer spheroids (LCS), self-renewal, expression of stemness markers and tumorigenic potential of human immortalized bronchial cells (BEAS-2B) ... See full document
6
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
... ATM mutations have a twofold higher breast cancer ...ATM mutations are likely linked to an increased level of sensitivity to platinum-based antineoplastic drugs [110, ...addition, inhibition of DDR ... See full document
21
Expression of HSP90AA1/HSPA8 in hepatocellular carcinoma patients with depression
... proportion of patients suffer depression and that this may affect prognosis. Posthepatectomy DFS in our cohort was significantly longer, and DFS rates higher, among patients with no or mild depression than among those ... See full document
27
Activation of SGK1 in endometrial epithelial cells in response to PI3K/AKT inhibition impairs embryo implantation
... in AKT activity ...and AKT, two closely related kinases [20]. If correct, inhibition of the PI3K/ AKT pathway could constitute a strategy to enhance SGK1 activity, thereby preventing embryo ... See full document
124
Dabrafenib and its potential for the treatment of metastatic melanoma
... primary aim of the study was to establish safety, tolerability, and the recommended phase 2 dose (RP2D) of dabrafenib. Secondary objectives were to determine pharmacokinetic and pharmacodynamic profiles and tumor ... See full document
12
Extensive alterations of the whole-blood transcriptome are associated with body mass index: results of an mRNA profiling study involving two large population-based cohorts
... The pathomechanisms underlying vascular and non- vascular complications related to insulin resistance, metabolic syndrome and T2D have not been com- pletely resolved yet. Recent epidemiological evidence suggests a ... See full document
10
NANO DELIVERY: A SMART CARRIER FOR TREATMENT OF OVARIAN CANCER
... p53 mutations (95-97% of cases) and marked genomic instability resulting in frequent somatic copy number alterations (amplifications or ...oncogenic mutations are rare, but amplifications of the p110 ... See full document
20
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
... In a clinical trial to assess whether VPA can modulate the effectiveness of temozolomide radiochemotherapy in patients with glioblastoma, it was suggested the combined therapy with VPA was more effective over patients ... See full document
37
Next generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
... Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.. Herry[r] ... See full document
67
Original Article Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization
... In summary, our data show that p-mTOR expres- sion occurs frequently in CRC with a clear pref- erence for left-sided tumors. The high frequen- cy and overexpression of p-mTOR provides fur- ther rationale for ... See full document
65
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
... The Akt1/2 kinase inhibitor showed a growth inhibitory effect in two of the trastuzumab non-responsive cell lines (KPL4 and ...Two Akt inhibitors were included in the compound library: API2 and ... See full document
33
Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010–2013
... The study cohort comprised patients who met the following inclusion criteria: 1) diagnosed with incident breast, lung, gastric, ovarian, or colorectal cancer at age 18 o[r] ... See full document
10
Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells
... of AKT plays a major role in triggering EMT in colon cancer cells, suggesting that targeting AKT signaling could lead to the inhibition of EMT and ultimately less invasive ...override ... See full document
105
Profile of neratinib and its potential in the treatment of breast cancer
... As a result, lapatinib has been taken into clinical trials in melanoma, where patients with no more than two oncogenic somatic HER4 mutations will be offered lapatinib mono- therapy (NCT01264081). Being an ... See full document
78
Related subjects